NRIX Nurix Therapeutics, Inc.
FY2025 10-K
Nurix Therapeutics, Inc. (NRIX) filed its fiscal year 2025 10-K annual report with the SEC on Jan 28, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Clinical stage biopharma focused on targeted protein degradation using AI-integrated DEL-AI platform for oncology, inflammation, and immunology treatments
- • Advanced lead BTK degrader bexobrutideg in Phase 2 pivotal trial with FDA Fast Track and EMA PRIME designations for relapsed/refractory CLL and WM
Management Discussion & Analysis
- • No revenue figures or profitability metrics disclosed in provided text
- • No segment performance data available
Risk Factors
- • Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024
- • Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel
Financial SummaryXBRL
Revenue
$84M
Net Income
-$264M
Operating Margin
-340.2%
Net Margin
-314.9%
ROE
-49.1%
Total Assets
$688M
EPS (Diluted)
$-3.05
Operating Cash Flow
-$249M
Source: XBRL data from Nurix Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nurix Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.